Current literature carries on to guidance the security of dual therapy as opposed to monotherapy. In 2017, the FDA permitted the security of twin therapy in asthmatic patients whilst warning in opposition to the usage of monotherapy of LABAs. The Global Initiative for COPD and National Asthma School